Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against DXC Technology Company (NYSE: DXC). Investor losses must relate to purchases of the Company’s shares between the expanded period of February 8, 2018 and November 6, 2018. This action is pending in the United States District Court for the Eastern District of Virginia.

What You May Do

If you purchased shares of DXC and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-dxc/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by February 25, 2019.

About the Lawsuit

On November 6, 2018, DXC disclosed a range of adverse information, including the loss of sales to significant customers, quarterly revenue shortfall in the hundreds of millions of dollars, and an $800 million reduction to its 2019 revenue outlook.

On this news, the price of DXC’s shares plummeted.

The case is City of Warren Police and Fire Retirement System v. DXC Technology Company, et al., No. 18-cv-1599.

About Kahn Swick & Foti, LLC

KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.